Senator Investment Group LP Has $7.74 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Senator Investment Group LP decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 10.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 90,000 shares of the company's stock after selling 10,000 shares during the quarter. Senator Investment Group LP's holdings in Novo Nordisk A/S were worth $7,742,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Victory Capital Management Inc. raised its holdings in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after buying an additional 23,223 shares in the last quarter. Norman Fields Gottscho Capital Management LLC lifted its holdings in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock worth $5,482,000 after purchasing an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC lifted its holdings in Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after purchasing an additional 30,420 shares during the last quarter. Versant Capital Management Inc bought a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $86,000. Finally, Talbot Financial LLC acquired a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $4,066,000. Institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on NVO. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. BNP Paribas initiated coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, April 15th. Finally, UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $135.00.

Novo Nordisk A/S Trading Down 7.8 %

Shares of NVO stock opened at $57.99 on Monday. The firm has a fifty day moving average of $75.52 and a 200-day moving average of $91.38. The stock has a market cap of $260.23 billion, a price-to-earnings ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a 52-week low of $57.28 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were given a $0.7874 dividend. The ex-dividend date of this dividend was Monday, March 31st. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is 49.54%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.